GlucoTrack Stock Scheduled to Reverse Split on Monday, May 20th (NASDAQ:GCTK)

Shares of GlucoTrack, Inc. (NASDAQ:GCTKFree Report) are scheduled to reverse split before the market opens on Monday, May 20th. The 1-5 reverse split was announced on Monday, May 20th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, May 20th.

GlucoTrack Trading Up 2.0 %

NASDAQ GCTK opened at $0.50 on Friday. GlucoTrack has a 52 week low of $0.13 and a 52 week high of $0.99. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.22 and a current ratio of 3.22. The stock’s 50 day moving average price is $0.47 and its two-hundred day moving average price is $0.32. The stock has a market capitalization of $13.38 million, a price-to-earnings ratio of -1.22 and a beta of 0.10.

GlucoTrack (NASDAQ:GCTKGet Free Report) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.10) EPS for the quarter.

Insider Activity

In other GlucoTrack news, Director Drew Sycoff purchased 182,540 shares of GlucoTrack stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average price of $1.26 per share, for a total transaction of $230,000.40. Following the completion of the acquisition, the director now owns 2,951,258 shares of the company’s stock, valued at approximately $3,718,585.08. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 17.70% of the stock is currently owned by insiders.

About GlucoTrack

(Get Free Report)

GlucoTrack, Inc, a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.

See Also

Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.